StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a research note released on Saturday. The firm issued a buy rating on the stock.
A number of other research firms also recently issued reports on MEIP. Brookline Capital Management downgraded shares of MEI Pharma from a strong-buy rating to a hold rating in a research report on Monday, July 22nd. Laidlaw downgraded MEI Pharma from a buy rating to a hold rating in a research note on Tuesday, July 23rd. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and an average target price of $7.00.
Read Our Latest Research Report on MEI Pharma
MEI Pharma Stock Performance
MEI Pharma (NASDAQ:MEIP – Get Free Report) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.35. As a group, equities analysts predict that MEI Pharma will post -5.1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MEI Pharma
An institutional investor recently raised its position in MEI Pharma stock. National Bank of Canada FI raised its holdings in shares of MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) by 43.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,000 shares of the company’s stock after buying an additional 10,000 shares during the period. National Bank of Canada FI owned about 0.50% of MEI Pharma worth $94,000 at the end of the most recent reporting period. Institutional investors own 52.38% of the company’s stock.
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Further Reading
- Five stocks we like better than MEI Pharma
- What is a buyback in stocks? A comprehensive guide for investors
- CarMax’s Impressive Rally: What Investors Should Watch Next
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 9/23 – 9/27
- Roth IRA Calculator: Calculate Your Potential Returns
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.